W. L. Gore & Associates, Inc. Release: Post-Market Approval Study of GORE(R) VIABAHN(R) Endoprosthesis with Heparin Bioactive Surface for Lower Limb Vascular Disease Completes Patient Enrollment

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) reported the complete enrollment in a post-market approval study designed to better characterize the performance of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in treating peripheral vascular disease (PVD) of the superficial femoral artery (SFA). The 11 participating sites enrolled a total of 120 patients in the Gore VIPER (GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface for SuPERficial Femoral Artery Endoluminal Bypass) Study since initiation.